Previous 10 |
BOSTON, July 19, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Allison Dorval, ...
We have witnessed a record last week, with 19 launched IPOs and almost $10 billion raised. That is the most companies in one week since 2004. Even more, the NYSE floor which has been rather quiet in the past year came back to life. SPACs have been favored for a good part of 2020 and the beg...
Last week turned out to be the busiest IPO week since 2004. Nearly $10 billion was raised in 19 public offerings. DiDi Global (NYSE: DIDI), a Chinese ride-hailing app with 15 million drivers across 4,000 towns and cities, led the way by raising $4.4 billion at a $70.4 billion market cap. Se...
In the US IPO market’s busiest week since 2004, 19 IPOs raised nearly $10 billion, led by Chinese ride-hailing giant DiDi Global. Cybersecurity platform SentinelOne (S) upsized and priced above the upwardly revised range to raise $1.2 billion at a $10.6 billion market cap....
Aerovate Therapeutics ([[AVTE]] +2.7%) has closed its upsized $139.8M IPO.The IPO of 9,984,463 shares was set at $14 per share. This included the underwriters' option to purchase 1,302,321 shares.Jefferies, Cowen, and Evercore were joint book-runners. Wedbush was lead manager.Shares bega...
BOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the closing of its upsized initial ...
News, Short Squeeze, Breakout and More Instantly...
Aerovate Therapeutics Inc. Company Name:
AVTE Stock Symbol:
NASDAQ Market:
Aerovate Therapeutics Inc. Website:
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the I nhaled i M atinib P ulmonary A rterial H ypertension C linical T rial (IMPA...
ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securities laws. On June 17, 2024, Aerovate announced topline results from...